Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
NCT04472429
Active Not Recruiting
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: The University of Arizona Cancer Center, Tucson, Arizona +83 locations
Conditions: Squamous Cell Carcinoma of the Anal Canal
Register for Updates
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
NCT01358877
Completed
This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona +555 locations
Conditions: Breast Cancer
Register for Updates
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in MTNBC
NCT06351332
Recruiting
This research is being done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer. The names of the study drugs involved in this study are: * Azenosertib (a type of WEE1 inhibitor) * Carboplatin (a type of platinum compound) * Pembrolizumab (a type of monoclonal antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
Register for Updates
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
NCT01993810
Active Not Recruiting
This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as photon or proton beam radiation therapy, may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as paclitaxel, carboplatin, eto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: University of Florida Health Science Center - Jacksonville, Jacksonville, Florida +29 locations
Conditions: Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients with Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT03132532
Completed
This randomized phase II trial studies how well platinum doublet chemotherapy and proton beam radiation therapy work in treating patients with stage II-III non-small cell lung cancer that cannot be removed by surgery (unresectable). Drugs used in chemotherapy, such as carboplatin, paclitaxel, etoposide, cisplatin, and pemetrexed work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation ther... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +1 locations
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Register for Updates
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
NCT04923776
Terminated
The purpose of this study is to evaluate whether radiation treatment directed at liver metastases can be safely added to standard of care treatment for extensive stage small cell lung cancer (ES-SCLC). The current standard treatment for people who have ES-SCLC is chemotherapy including drugs called carboplatin and etoposide, that is combined with a type of immunotherapy called atezolizumab. However, patients with liver involvement of their ES-SCLC don't respond as well to this treatment. The stu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York
Conditions: Small-cell Lung Cancer
Register for Updates
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT01154920
Active Not Recruiting
The goal of this clinical research study is to learn which chemotherapy combination is more effective in treating locally advanced head and neck squamous cell carcinoma. The side effects of these combinations will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)
NCT03918278
Active Not Recruiting
This is a 2 part study. Part 1 is a dose escalation to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) dose of MK-0482 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with advanced solid tumors for which there is no available therapy which may convey clinical benefit. Part 2 is expansion cohort to determine safety and tolerability of MK-0482 in combination with pembrolizumab with and without chemothe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Henry Ford Health System ( Site 0002), Detroit, Michigan +15 locations
Conditions: Neoplasms
Register for Updates
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
NCT06318897
Recruiting
To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Register for Updates
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
NCT05027633
Recruiting
This is a single arm phase II study that will evaluate the combination of pembrolizumab, docetaxel, and cisplatin or carboplatin (PDC) as single treatment modality in patients with stage II-IVb (T2-4, any N, M0) squamous cell carcinoma of the nasal cavity/paranasal sinuses (PNS SCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Squamous Cell Carcinoma, the Nasal Cavity, Paranasal Sinuses
Register for Updates
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933
Recruiting
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
12/09/2024
Locations: HonorHealth Research Institute, Scottsdale, Arizona +33 locations
Conditions: Colorectal Adenocarcinoma, Ewing Sarcoma
Register for Updates
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
NCT03215706
Completed
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Memorial Health Systems, Colorado Springs, Colorado +115 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates